These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 32716114)

  • 1. A randomized, double-blind, placebo-controlled, phase 3 study of tivantinib in Japanese patients with MET-high hepatocellular carcinoma.
    Kudo M; Morimoto M; Moriguchi M; Izumi N; Takayama T; Yoshiji H; Hino K; Oikawa T; Chiba T; Motomura K; Kato J; Yasuchika K; Ido A; Sato T; Nakashima D; Ueshima K; Ikeda M; Okusaka T; Tamura K; Furuse J
    Cancer Sci; 2020 Oct; 111(10):3759-3769. PubMed ID: 32716114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study.
    Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V; Mathurin P; Rota Caremoli E; Porta C; Daniele B; Bolondi L; Mazzaferro V; Harris W; Damjanov N; Pastorelli D; Reig M; Knox J; Negri F; Trojan J; López López C; Personeni N; Decaens T; Dupuy M; Sieghart W; Abbadessa G; Schwartz B; Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J
    Lancet Oncol; 2018 May; 19(5):682-693. PubMed ID: 29625879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.
    Santoro A; Rimassa L; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; Kolligs FT; Weiss A; Miles S; Gasbarrini A; Lencioni M; Cicalese L; Sherman M; Gridelli C; Buggisch P; Gerken G; Schmid RM; Boni C; Personeni N; Hassoun Z; Abbadessa G; Schwartz B; Von Roemeling R; Lamar ME; Chen Y; Porta C
    Lancet Oncol; 2013 Jan; 14(1):55-63. PubMed ID: 23182627
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors.
    Okusaka T; Aramaki T; Inaba Y; Nakamura S; Morimoto M; Moriguchi M; Sato T; Ikawa Y; Ikeda M; Furuse J
    Cancer Sci; 2015 May; 106(5):611-7. PubMed ID: 25711511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity
    Rebouissou S; La Bella T; Rekik S; Imbeaud S; Calatayud AL; Rohr-Udilova N; Martin Y; Couchy G; Bioulac-Sage P; Grasl-Kraupp B; de Koning L; Ganne-Carrié N; Nault JC; Ziol M; Zucman-Rossi J
    Clin Cancer Res; 2017 Aug; 23(15):4364-4375. PubMed ID: 28246274
    [No Abstract]   [Full Text] [Related]  

  • 6. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?
    Zhao S; Wu W; Jiang H; Ma L; Pan C; Jin C; Mo J; Wang L; Wang K
    Front Immunol; 2021; 12():731527. PubMed ID: 34804015
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tivantinib (ARQ197) in hepatocellular carcinoma.
    Porta C; Giglione P; Ferrari A; Reversi F; Liguigli W; Imarisio I; Ganini C
    Expert Rev Anticancer Ther; 2015 Jun; 15(6):615-22. PubMed ID: 26035719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib.
    Rimassa L; Abbadessa G; Personeni N; Porta C; Borbath I; Daniele B; Salvagni S; Van Laethem JL; Van Vlierberghe H; Trojan J; De Toni EN; Weiss A; Miles S; Gasbarrini A; Lencioni M; Lamar ME; Wang Y; Shuster D; Schwartz BE; Santoro A
    Oncotarget; 2016 Nov; 7(45):72622-72633. PubMed ID: 27579536
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
    Yoshioka H; Azuma K; Yamamoto N; Takahashi T; Nishio M; Katakami N; Ahn MJ; Hirashima T; Maemondo M; Kim SW; Kurosaki M; Akinaga S; Park K; Tsai CM; Tamura T; Mitsudomi T; Nakagawa K
    Ann Oncol; 2015 Oct; 26(10):2066-72. PubMed ID: 26153496
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis.
    Wang Y; Xu H; Yang J; Zhang J
    Medicine (Baltimore); 2023 Apr; 102(16):e32591. PubMed ID: 37083791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tivantinib in hepatocellular carcinoma.
    Trojan J; Zeuzem S
    Expert Opin Investig Drugs; 2013 Jan; 22(1):141-7. PubMed ID: 23167786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tivantinib: critical review with a focus on hepatocellular carcinoma.
    Rota Caremoli E; Labianca R
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1563-74. PubMed ID: 25307444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tivantinib, a new option for second-line treatment of advanced hepatocellular carcinoma? The experience of Italian centers.
    Rimassa L; Santoro A; Daniele B; Germano D; Gasbarrini A; Salvagni S; Masi G; Abbadessa G; Lamar M; Goldberg T; Porta C
    Tumori; 2015; 101(2):139-43. PubMed ID: 25838254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tivantinib for the treatment of hepatocellular carcinoma.
    Best J; Schotten C; Lohmann G; Gerken G; Dechêne A
    Expert Opin Pharmacother; 2017 May; 18(7):727-733. PubMed ID: 28414564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II trial of a selective c-Met inhibitor tivantinib (ARQ 197) monotherapy as a second- or third-line therapy in the patients with metastatic gastric cancer.
    Kang YK; Muro K; Ryu MH; Yasui H; Nishina T; Ryoo BY; Kamiya Y; Akinaga S; Boku N
    Invest New Drugs; 2014 Apr; 32(2):355-61. PubMed ID: 24337769
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis.
    Santoro A; Simonelli M; Rodriguez-Lope C; Zucali P; Camacho LH; Granito A; Senzer N; Rimassa L; Abbadessa G; Schwartz B; Lamar M; Savage RE; Bruix J
    Br J Cancer; 2013 Jan; 108(1):21-4. PubMed ID: 23287988
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
    Sequist LV; von Pawel J; Garmey EG; Akerley WL; Brugger W; Ferrari D; Chen Y; Costa DB; Gerber DE; Orlov S; Ramlau R; Arthur S; Gorbachevsky I; Schwartz B; Schiller JH
    J Clin Oncol; 2011 Aug; 29(24):3307-15. PubMed ID: 21768463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Zhu AX; Kang YK; Yen CJ; Finn RS; Galle PR; Llovet JM; Assenat E; Brandi G; Pracht M; Lim HY; Rau KM; Motomura K; Ohno I; Merle P; Daniele B; Shin DB; Gerken G; Borg C; Hiriart JB; Okusaka T; Morimoto M; Hsu Y; Abada PB; Kudo M;
    Lancet Oncol; 2019 Feb; 20(2):282-296. PubMed ID: 30665869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 1 dose-escalation trial evaluating the combination of the selective MET (mesenchymal-epithelial transition factor) inhibitor tivantinib (ARQ 197) plus erlotinib.
    Goldman JW; Laux I; Chai F; Savage RE; Ferrari D; Garmey EG; Just RG; Rosen LS
    Cancer; 2012 Dec; 118(23):5903-11. PubMed ID: 22605616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma.
    Xiang Q; Zhen Z; Deng DY; Wang J; Chen Y; Li J; Zhang Y; Wang F; Chen N; Chen H; Chen Y
    J Exp Clin Cancer Res; 2015 Oct; 34():118. PubMed ID: 26458953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.